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Abstract
Background: Infection is a main cause of morbidity and mortality after heart surgery, with multi-resistant pathogens
increasingly representing a challenge. Daptomycin provides bactericidal activity against gram-positive organisms that
are resistant to standard treatment including vancomycin.
Methods: A cohort of cardiac surgical patients, treated with daptomycin for major infection at two tertiary care centers,
were retrospectively studied with a particular focus on the type of infection, causative pathogens and co-infections,
daptomycin dosage, adverse events and outcome in order to provide evidence for the efficiency and safety of
daptomycin in a distinct high-risk patient population.
Results: Sixty-five patients (87.7 % males, 60.4 ± 13.5 years) who had undergone aortic surgery (20.0 %), ventricular assist
device (VAD) implantation (21.5 %), combined procedures (21.5 %), coronary artery bypass grafting (12.3 %), isolated
valve surgery (15.4 %) and heart transplantation (7.7 %) were diagnosed with catheter-related infection (26.1 %), valve
endocarditis (18.8 %), sternal wound (13.0 %), VAD-associated (11.6 %), cardiac implantable electrophysiological device
(CIED)-associated (4.1 %), respiratory tract (4.3 %), bloodstream (4.3 %) and other infection (4.3 %). In 13.0 %, no focus of
infection was identified though symptoms of severe infection were present. The most frequent pathogens were
Staphylococcus epidermidis (30.4 %), Staphylococcus aureus (23.1 %) and Enterococcus species (10.1 %). Daptomycin
doses ranging from 3 mg/kg every 48 h to 10 mg/kg every 24 h were administered for 15.4 ± 11.8 days. 87.0 % of the
cases were classified as success, 7.2 % as treatment failure and 5.8 as non-evaluable. Adverse events were limited to
one case of mild and one case of moderate neutropenia with recovery upon termination of treatment.
Conclusion: Daptomycin proved safe and effective in major infection in high-risk cardiac surgical patients.
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Background
Major infection is a severe complication in cardiac surgical
patients and may consist of sternal wound infection,
bloodstream or catheter-related infection, native or pros-
thetic valve endocarditis, or infection associated with other
implantable devices such as CIEDs, VADs or vascular
prosthetic material. Recent investigations of large patient
cohorts showed incidences of major infection after cardiac
surgery amounting to up to nearly 5 % [1–8]. Investigation
into the microbiological features of major infections in car-
diac surgical patients showed that the majority of isolates
are gram-positive [2, 7, 9–13]. As the number of gram-
positive bacteria, resistant to standard treatment (amino-
penicillins or cephalosporines) is substantial, the initial
choice of drug is of utmost importance [14–16].
Vancomycin, the first-choice drug used against
methicillin-resistant gram-positive pathogens, is associ-
ated with considerable side effects. Of these, nephrotox-
icity is particularly unfavorable in the cardiac surgical
population in whom acute kidney injury was reported to
occur at a rate of up to 30 % and subtle renal injury is
present in virtually all patients in the early postoperative
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phase [17–19]. Additionally, vancomycin does not achieve
high tissue levels and has limited activity in the biofilm
layer on implanted materials. Correct dosage requires
drug monitoring and continuous application, which is cur-
rently favored, is not suitable for general wards [20–22].
Therefore, the introduction of alternative substances such
as linezolid, tigecyclin, quinupristin-dalfopristin and dap-
tomycin has met with particular interest [23].
Daptomycin is a cyclic lipopeptide derived from Strepto-
myces roseosporus as a fermentation product and has rapid
concentration-dependent bactericidal activity against
most gram-positive pathogens including methicillin-
resistant Staphylococcus aureus (MRSA), vancomycin
intermediate susceptible Staphylococcus aureus and
vancomycin-resistant enterococci [24–28]. In 2003, the U.S.
Food and Drug Administration (FDA) approved daptomy-
cin for the treatment of complicated skin and soft tissue in-
fections, and in 2006, an additional FDA approval was
granted for the treatment of bloodstream infections and
right-sided endocarditis. In Europe, Daptomycin was ap-
proved for the treatment of complicated skin and soft tissue
infections in 2006, and for the treatment of Staphylococcus
aureus right-sided infective endocarditis and bacteremia in
2007 [29–31]. Among the anti-infective substances recently
introduced, daptomycin stands out for its excellent tissue
penetration, killing rate and penetration into biofilm layers.
The aim of the present study is to review our clinical
experience with daptomycin for the treatment of major
gram-positive infections after heart surgery with a focus
on safety, tolerability and efficacy, thus providing com-
plementary insight into the application of daptomycin in
challenging infections in a highly specific patient cohort.
Methods
Patients, definitions and data collection
We retrospectively identified all consecutive adult car-
diac surgical patients with major infective complications
after cardiac surgery who were treated with daptomycin
at two tertiary centers from 2008 to 2009 and from 2011
to 2014, respectively. None of the patients were treated
with daptomycin in the setting of a clinical trial. The pa-
tients at the first center provided informed consent for
retrospective evaluation of their data including reporting
to the European Cubicin (Novartis Pharma GmbH, Nur-
emberg, Germany) Outcomes Registry and Experience
(EU-CORE) database. For the part of the study imple-
mented at the second center, institutional review board
approval including a waiver of informed consent was
granted (AZ 511/15).
Data were obtained by reviewing medical records with
a special focus on signs and symptoms of infection, on
the one hand, and findings potentially indicating adverse
effects of daptomycin, on the other. Diagnosis of infec-
tion relied on clinical assessment, imaging, laboratory
parameters and microbiological findings. Therapy with
daptomycin was instituted at the discretion of the senior
physicians in charge of the respective intensive care unit
(ICU) and independently of the present study, which is a
purely retrospective analysis of daptomycin use that was
not initiated until after completion of treatment in all
patients enrolled.
The clinical outcomes upon completion of daptomycin
therapy were retrospectively evaluated and classified as
“success” where clinical signs and symptoms were found
to have resolved and/or cultures returned negative and/or
infection markers decreased. Outcomes were classified as
“non-evaluable” where the response to therapy with dap-
tomycin could not be determined, for example due to the
effects of secondary infection or insufficient data, and as
“failure” where the infection treated with daptomycin per-
sisted, worsened or recurred.
Statistical analysis
Descriptive statistics were calculated using means and
standard deviations, frequencies and percentages as ap-
propriate. Data analysis was performed using SPSS 22.0
(SPSS, Inc., Chicago, US).
Results
Daptomycin was administered in 69 cases of major infec-
tion in 65 patients (mean age 60.4 ± 13.5 years, 87.7 %
male). Two patients had more than one course of dapto-
mycin treatment, with the subsequent courses not related
to the respective initial infection. Demographic parame-
ters and baseline characteristics, as well as diagnostics,
treatment and outcomes are summarized in Table 1.
In 79.7 % of the cases, patients had received antibacter-
ial treatment with other substances including penicillins,
cephalosporins, carbapenems, aminoglycosides, glycopep-
tides and oxazolidinones before the first dose of daptomy-
cin. In 5 cases of endocarditis, daptomycin was initiated
before surgery. In all other cases, daptomycin was admin-
istered after cardiac surgical procedures.
The study cohort comprised 13 (20.0 %) patients who
had undergone aortic surgery including isolated aortic
valve replacement as well as aortic replacement proce-
dures. 14 (21.5 %) patients each had undergone VAD im-
plantation and combined procedures. CABG had been
performed in 8 (12.3 %) further patients, isolated valve
surgery in 10 (15.4 %) and heart transplantation in 5
(7.7 %). A total of 32 (67.7 %) were classified as high-risk
procedures.
Investigation of the initial focus of infection showed that
central venous catheter-associated infection (n = 16, 23.2 %)
was the most frequent indication for treatment with dapto-
mycin, followed by valve endocarditis (n = 13, 18.8 %), ster-
nal wound infection (n = 9, 13.0 %) and VAD-associated
infection (n = 8, 11.6 %). CIED-associated, respiratory tract
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and bloodstream infection accounted for 3 (4.3 %) cases
each, 2 (2.9 %) patients were diagnosed with infection of ar-
terial lines, and 3 (4.3 %) with other infection. No focus of
infection was identified in 9 (13.0 %) cases.
Staphylococcus epidermidis (n = 21, 30.4 %) was the
most frequent pathogen isolated, followed by methicillin
resistant (n = 9, 13.0 %) and methicillin-susceptible (n = 7,
10.1 %) Staphylococcus aureus and Enterococcus species
(n = 7, 10.1 %). No causative organism was identified in 19
(27.5 %) cases. Secondary infection was present in 34
(49.3 %) cases, with fungal pathogens accounting for
70.6 % (n = 24) of the secondary infections. The remaining
secondary infections were caused by gram-negative rods
(n = 6, 17.6 %), Staphylococcus aureus (n = 2, 5.9 %),
coagulase-negative Staphylococcus species (n = 1, 2.9 %)
and Propionibacterium acnes (n = 1, 9.1 %).
In a third of the cases (n = 23, 33.3 %), a causative or-
ganism was identified by microbiological examination of
Table 1 Summary of baseline, infection, diagnostic, treatment and outcome parameters
Demographic data and comorbidities (patients, n = 65) Cardiac surgical procedure (patients, n = 65)
Age [years] Mean 60.44 ± 13,51 Aortic surgery 13 (20.0 %)
Male 57 (87.7 %) VAD implantation 14 (21.5 %)
Weight [kg] Mean 80.57 ± 14.64 Combined procedures 14 (21.5 %)
Diabetes 17 (26.2 %) CABG 8 (12.3 %)
COPD 6 (9.2 %) Isolated valve surgery 10 (15.4 %)
Rheumatic disease 1 (1.5 %) Heart transplantation 5 (7,7 %)
Hemodialysis 9 (13.8 %) CABG + CIED removal 1 (1.5 %)
Classified as multi-morbid 31(47.7 %) Classified as high-risk procedure 32 (67.7 %)
Focus of infection (courses of treatment, n = 69) Pathogens isolated (courses of treatment, n = 69)
Central venous catheter-
associated infection
16 (23.2 %) Staphylococcus epidermidis 21 (30.4 %)
Valve endocarditis 13 (18.8 %) Staphylococcus aureus, MRSA 9 (13.0 %)
Sternal wound infection 9 (13.0 %) Staphylococcus aureus, MSSA 7 (10.1 %)
VAD-associated infection 8 (11.6 %) Enterococcus spp. 7 (10.1 %)
CIED-associated infection 3 (4.3 %) Other 6 (8.7 %)
Respiratory tract infection 3 (4.3 %) No causative organism identified 19 (27.5 %)
Bloodstream infection 3 (4.3 %)
Infection of arterial lines 2 (2.9 %)
Other infection 3 (4.3 %)
No focus of infection identified 9 (13.0 %)
Secondary infection (courses of treatment, n = 69) Diagnostics (courses of treatment, n = 69)
Present in 34 (49.3 %) Clinical signs and symptoms only 15 (21.7 %)
Fungal pathogen 24 (70.6 %) Positive swab/tissue sample from infection site 23 (33.3 %)
Gram-negative rods 6 (17.6 %) Positive blood culture 15 (21.7 %)
Staph. aureus 2 (5.9 %) Echocardiographic findings 13 (18.8 %)
Coagulase-negative staphylococcus 1 (2.9 %) CT findings 4 (5.8 %)
Propionibacterium acnes 1 (9.1 %) Positive culture from catheter tip 15 (21.7 %)
Multiple diagnostics 10 (14.5 %)
Surgical/interventional measures (courses of treatment, n = 69) Classification of outcome (courses of treatment, n = 69)
Valve replacement for endocarditis 12 (17.4 %) Success 60 (87.0 %)
Wound debridement (with/without
removal of foreign material,
placement of drains, vacuum
assisted closure)
17 (24.6 %) Failure 5 (7.2 %)
Removal of infected venous or
arterial catheters
19 (27.5 %) Non-evaluable 4 (5.8 %)
Placement of drains 2 (2.9 %)
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swabs or tissues from the infection sites. Blood cultures
and cultures from catheter tips were positive in 15
(21.7 %) cases each. Echocardiographic and CT findings
supported the diagnosis of major infection in 13 (18.8 %)
and 4 (5.8 %) of the cases, and 15 (21.7 %) cases were di-
agnosed on the basis of clinical signs and symptoms
only. In 10 (21.7 %) cases, the diagnosis of major infec-
tion was established using more than one diagnostic
modality.
Treatment with daptomycin lasted 15.4 ± 11.8 days
(range 2–92 days). In all but 12 (17.4 %) cases, patients
received daptomycin once daily. Doses ranged from
3 mg/kg at intervals of 48 h to 10 mg/kg at intervals of
24 h. The median dose was 6 mg/kg/24 h and adminis-
tered in 20 (29.05) cases, while doses exceeding 6 mg/
kg/day were administered in 15 (21.7 %) cases. Patients
with sternal wound infection received between 5 mg/kg
and 8 mg/kg at intervals of 24 h, those with catheter-
related infection from 3 mg/kg at intervals of 48 h to
7 mg/kg at intervals of 24 h, those with VAD-associated
infection between 3 mg/kg and 7 mg/kg per day, and
those with endocarditis up to 10 mg/kg per day.
The courses of daptomycin for VAD-associated infec-
tion, of which three were administered for mediastinitis
with VAD involvement, two for deep driveline infection,
and one each for abdominal wall abscess with driveline
involvement, thoracic wall abscess with VAD involve-
ment and intrapericardial hematoma and intrathoracic
abscesses, showed considerable variation and consisted
of between 3 mg and 7 mg/kg per day.
Interventional measures or surgical therapy supplement-
ing the antimicrobial regimen were performed in 50
(72.5 %) of the cases. Removal of infected catheters (n =
19, 27.5 %) was the most frequent supplementary meas-
ure, followed by wound debridement (n = 17, 24.6 %) with
or without removal of foreign material, placement of
drains and/or vacuum-assisted closure. Valve replacement
for endocarditis was performed in 12 (17.4 %) cases, and
drains were placed in 2 (2.9 %).
The vast majority of cases (n = 60, 87.0 %) were classi-
fied as success. 4 (5.8 %) were classified as “non-evaluable”
because improvement could not be assessed due to sec-
ondary infection, severe deterioration and death for other
causes, or insufficient data. 5 (7.2 %) cases were classified
as “failure” because infection persisted or kept returning.
Serum creatinine was determined once or twice daily
in the course of routine ICU panels. The baseline creatin-
ine clearance, defined as the level before the first dose of
daptomycin, was 54.3 ± 38.7 ml/min. Upon completion of
treatment with daptomycin, a creatinine clearance of 53.7
± 42.5 ml/min was measured. A significant deterioration
of creatinine clearance and need for renal replacement
therapy during daptomycin treatment was noted only in a
patient who received 3 courses of daptomycin for deep
sternal wound infection with VAD involvement at inter-
vals of > 1 month and experienced multi-organ failure sec-
ondary to sepsis and heart failure.
Creatinine phosphokinase (CPK) levels were monitored
closely at both centers. Increases occurred in nearly all pa-
tients, but as fluctuations were found to be associated with
cardiac surgery, no valid conclusion could be drawn from
the evaluation of CPK values at baseline, during and after
daptomycin. Monitoring of white blood cell (WBC) levels
for leukopenia yielded minimum values between 1.9 G/l
and 19.4 G/l. A drop in WBC to values below the normal
range was noted only in two patients of whom one showed
only temporary mild leukopenia with a minimum WBC
count of 3.46 G/L. In the second, a decrease from 12.6 G/
L to 1.72 G/L during daptomycin treatment with a recov-
ery to 3.35 G/L upon termination of treatment was noted.
Beyond this, no adverse events or undesired side effects at-
tributable to daptomycin treatment were registered.
Discussion
The outcomes of our previous work, which demonstrated
the efficacy of daptomycin in cardiac surgical patients [32],
are confirmed by the results of the present study. With
87.0 % of the cases assessed as clinical success and 7.2 %
as treatment failure, our current results are comparable to
the success and failure rates of 79 and 7.5 % reported by
the European Cubicin Outcome Registry and Experience
EU-CORE [33]. Our cohort, however, was highly specific
in that our patients had undergone a variety of mostly
high-risk cardiac surgical procedures that resulted in con-
siderable surgical trauma and the effects of cardiopulmo-
nary bypass adding to a post-surgical risk profile that
resulted not only from the underlying cardiac conditions,
but also from comorbidities, frailty, presence of foreign
material including heart valves and VADs and, in the case
of heart transplantation, need for immunosuppression. In
addition, a significant share of our patients were treated
for challenging conditions such as deep sternal wound in-
fection, CIED- or VAD-associated infection and endocar-
ditis, while skin and soft tissue infections made up 44 % of
the infections registered in the EU-CORE database, with
smaller numbers treated for bacteraemia (22 %), endocar-
ditis (12 %) or osteomyelitis (6 %).
In our patient cohort, endocarditis, sternal wound infec-
tion and VAD-associated infection were the most frequent
types of infection specific to cardiac surgical patients. Of
these, sternal wound infection has variously been found to
be a promising area of application for daptomycin, which
was reported to be safe and effective [32, 34] and to have
yielded favourable mid-term results [35]. With regard to
osteomyelitis not limited to the sternum, encouraging re-
sults for the application of daptomycin were published in
a number of single-center reports and reviews [36, 37], as
well as from the CORE and EU-CORE registries. In the
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EU-CORE database, 220 of 3621 patients registered from
2006 to 2010 were treated for osteomyelitis, with the most
common sites of infection being knees and hips, and the
most common pathogens Staphylococcus aureus and
coagulase-negative staphylococci. Cure and improval were
reported in 23 % and 52 % of patients treated for osteo-
myelitis, respectively, yielding an overall clinical success
rate of 75 %. Notably, success was similar between MRSA
and MSSA and lowest treatment failure rates were ob-
served for coagulase-negative staphylococcal pathogens
[38]. From the US-based CORE registry, improval rates ≥
90 % were reported for patients treated with daptomycin
for osteomyelitis, with a higher success rate in in-patients
vs. out-patients [39] and a trend towards higher improval
rates in patients receiving a daily dose of ≥ 6 mg/kg [40].
The issue of higher dosage in patients with particularly
severe infection, including osteomyelitis, was repeatedly
addressed, and it was pointed out that daptomycin was
well-tolerated at doses ≥ 6 mg per kg to which better
outcomes were attributed [37, 40–43]. The Infectious
Diseases Society of America, in its 2011 guidelines [44],
not only included daptomycin, though not licensed for
the treatment of osteomyelitis, as an option for the treat-
ment of MRSA osteomyelitis, but in keeping with the as-
sumption that higher daily dosages will compensate for
low vascularisation of bone tissue, recommended the
maximum approved daily dose of 6 mg/kg daptomycin.
Considering the data published to date, dosage and the
possibility to apply high-dose daptomycin regimens may
be assumed to be of special importance in the context of
osteomyelitis even though evaluation of the EU-CORE
database showed no dose-related outcomes in patients
treated for osteomyelitis [38].
When it comes to justifying administration of high-
dose daptomycin, cardiac surgical patients with sternal
wound infections represent a distinct subgroup in that
sternal osteomyelitis may rapidly progress to frank and
potentially lethal mediastinitis. Additionally, the issues of
bone penetration of antibiotics and vascularisation of os-
seous structures must be viewed against the background
of the fact that the sternal blood supply is impaired due
to sternotomy and sternal closure and, in the case of
CABG, unilateral or bilateral internal thoracic artery
harvesting. Nevertheless, data guiding daptomycin dos-
age in cases of sternal osteomyelitis and mediastinitis are
scarce. In our patients, those treated for sternal wound
infection received daptomycin at daily doses between 4
and 8 mg/kg, thus contrasting with previous authors
who reported administration of a standard daily dose of
6 mg/kg [45].
A role for high-dose daptomycin was also suggested
for the treatment of infective endocarditis (IE) including
left-sided and double-sided IE [43, 46–48]. Of the pa-
tients registered in the EU-CORE database from 2006 to
2010, 10 % were treated for IE including 69 % of left-
sided IE. The majority (59 %) received 6 mg/day, while
doses ≥ 6 and up to 12 mg/day were administered in
26 % of cases, with coagulase-negative staphylococcus
and Enterococcus faecalis associated with daptomycin
dosages exceeding 6 mg/kg [49].
Our patient cohort comprised 13 patients with IE.
Contrasting with a share of only 50 % in the EU-CORE
database [49], all but one treated for postoperative pros-
thetic valve endocarditis underwent surgical treatment.
This is noteworthy in that evaluation of EU-CORE regis-
try data showed that surgical intervention is typically as-
sociated with the most severe forms of IE, on the one
hand, and that patients receiving surgical intervention
had a higher success rate than those managed medically,
on the other [49]. The overall success rate determined
for treatment of IE in the framework of the EU CORE
registry was 80 % (91 % for right-sided and 76 % for left-
sided IE, and higher dosage regimens were found to be
associated with a higher success rate of 90 % in patients
treated with ≥ 8 mg/day (91 % for right-sided and 89 %
for left-sided IE) [49]. A slightly lower success rate of
85.9 %, with success and failure rates similar in the left
and right-sided IE groups, was reported from a multi-
centric study including 70 patients who received daily
doses between 8.2 and 10.0 mg/kg per day [47]. Add-
itionally, successful treatment of IE using daily doses up
to 12 mg/kg was reported [46, 50, 51]. This is in keeping
with the results of our retrospective analysis, which also
showed that the majority of patients treated for endocar-
ditis received ≥ 6 mg and up to 10 mg/kg per day.
In the report from the EU-CORE registry, it was addition-
ally pointed out that the rate of CIED-associated infections
and the number of patients requiring device extraction in
addition to antimicrobial therapy has risen substantially
over the past few years [49]. Though the number of patients
with CIED-associated infection in our patient cohort was
low, CIED-associated infection represents a potentially fatal
complication that requires aggressive treatment. This is
reflected by the fact that, in a recent study of 25 patients
treated for CIED-associated infection, daily doses between
6.4 and 10.7 mg/kg were administered, with lead extraction
performed in 88 % of patients. Treatment success was
80 %, with complete microbiological success observed in
92 % [52]. Of a further collective of nine patients treated for
CIED-associated infection with daptomycin, 7 had their
CIED removed. Eight patients, including those who did not
undergo system removal, were cured with a daily dosage of
6 mg/kg [53]. Further literature on treatment of CIED-
associated infection with daptomycin in scarce and mostly
limited to individual case reports [54–57] even though dap-
tomycin, with its ability to penetrate into biofilms [58–60], is
well suited for the treatment of CIED-associated infections,
which are characterized by biofilm development on leads.
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This particular aspect is shared by VAD-associated in-
fection, where biofilm development on device surfaces
and drivelines also renders the eradication of infection
difficult. Our study population comprised > 20 % of VAD
recipients, reflecting that antimicrobial treatment using
daptomycin was commenced as soon as major infection
in a VAD recipients was suspected. The particular sever-
ity of VAD-associated infection is reflected by the fact
that even though two of our VAD recipients received
three courses of daptomycin each, deep driveline infec-
tion kept recurring in one, while the other finally suc-
cumbed to fungal mediastinitis with VAD involvement.
Our retrospective analysis has shown that daptomycin
was frequently chosen for the treatment of VAD recipi-
ents because of its bactericidal activity against multi-
resistant gram-positive organisms, its good penetration
into biofilms, and because it has variously proven effi-
cient in treating infection in VAD recipients [61–63].
Of the remaining patients, those in whom the respira-
tory tract was designated as the primary focus of infec-
tion deserve mention because daptomycin is expressly
not recommended for treatment of pulmonary infections
[64, 65]. In these cases, the respiratory tract was indi-
cated as the initial focus of infection and the microbio-
logical results obtained from the patients’ respiratory
secretion served to guide antibiotic management, but
daptomycin was not chosen to treat gram-positive re-
spiratory tract infection as such, but to prevent seeding
of pathogens from the respiratory tract in severely com-
promised patients in an ICU setting.
In the largest subgroup of our patient cohort, i.e. pa-
tients with catheter-associated infections, we made more
liberal use of daptomycin than recommended by the In-
fectious Diseases Society of America in its 2009 Update
of its Clinical Practice Guidelines for the Diagnosis and
Management of Intravascular Catheter-Related Infection.
These recommend alternative agents such as daptomycin
for empirical therapy of catheter-related bloodstream infec-
tions in health care settings with an elevated prevalence of
MRSA in which the preponderance of MRSA isolates have
vancomycin minimum inhibitory concentration values >
2 μg/ml. Additionally, daptomycin is listed as an option in
patients with catheter-related bloodstream infection due to
ampicillin- and vancomycin-resistant enterococci and pa-
tients receiving hemodialysis with catheter-related blood-
stream infection due to vancomycin-resistant enterococci
[66]. In contrast to the dosages of 6 mg/kg and 6–8 mg/kg
per day recommended by these guidelines, our patients
with catheter-related infection mostly received dapto-
mycin at lower doses ranging from 3 mg/kg at intervals
of 48 h to 7 mg/kg at intervals of 24 h. Treatment suc-
cess in patients with catheter-related infection was
nevertheless achieved in 72.2 % of cases, compared to a
total success rate of 83.7 %.
Assessment of the overall outcome in our patient co-
hort yielded a favourable profile for daptomycin in terms
not only of efficacy and clinical success rates, but also
with regard to tolerability and safety even in high doses.
This applies, in particular, to muscle toxicity and drug-
related CPK elevations [33, 67, 68], which were reported
to have occurred more frequently in patients receiving
daily doses > 6 mg/kg [49], but also to renal impairment
[69, 70] and leukopenia [71, 72]. Regular monitoring of
our patients for CPK, creatinine clearance and WBC im-
plemented showed no relevant changes in creatine clear-
ance and CPK levels from baseline to completion that
were attributed to daptomycin, and only one case of
moderate leucopenia that resolved upon termination of
treatment.
Limitations
The shortcomings of the present study mainly consist in
its retrospective design, which rendered evaluation of
the treatment success difficult in some cases and led to
4 (5.8 %) cases being classified as “non-evaluable” be-
cause improvement could not be assessed due to sec-
ondary infection, severe deterioration and death for
other causes, or insufficient data.
Conclusions
In conclusion, daptomycin treatment was successful in the
clinical management of patients with major infection after
cardiac surgery and therefore represents a promising alter-
native to conventional antimicrobial treatment of challen-
ging infections in cardiac surgical patients. Our two-center
experience confirms efficacy, as well as tolerability and
non-toxicity, in a highly specific patient population that is
characterized by surgical trauma adding to cardiac mor-
bidity, comorbidity and frailty. Reports on higher doses in
patients treated for particularly severe infections yielding
improved success rates without causing more adverse
events warrant further investigation in cardiac surgical pa-
tients with major infection, too.
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